 |
|
RESEARCH LETTERS
Fifty-five Basal Cell Carcinomas Treated With Topical Imiquimod: Outcome at 5-Year Follow-up
David Vidal, MD, PhD;
Xavier Matías-Guiu, MD, PhD;
Agustín Alomar, MD, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Noninvasive immunobiologic therapy with topical imiquimod, 5%, cream is an emerging therapeutic option for basal cell carcinoma (BCC). Despite the documented short-term efficacy of imiquimod for superficial BCC, few data exist on the long-term course of imiquimod-treated BCCs. In an effort to evaluate the long-term outcome of patients treated with imiquimod for BCC, we conducted a 5-year follow-up, prospective, open-label study.
Methods
The sample size was 55 BCCs, and the cases were assigned to 2 groups consecutively: 35 BCCs were treated 3 times weekly for 8 weeks, and 20 BCCs were treated 5 times weekly for 5 weeks. Inclusion criteria were age 18 years or older; primary BCC larger than 8 mm; and a superficial, nodular, or infiltrative histologic pattern.1 Exclusion criteria were pregnancy; immunosuppression; and genetic predisposition to BCC and other histologic subtypes of BCC. Diagnosis was verified . . . [Full Text of this Article]
Results
Comment
AUTHOR INFORMATION
RELATED ARTICLE
Efficacy of Topical 5% Imiquimod Cream for the Treatment of Nodular Basal Cell Carcinoma: Comparison of Dosing Regimens
Stephen Shumack, June Robinson, Steven Kossard, Loren Golitz, Hubert Greenway, Arnold Schroeter, Kara Andres, Mark Amies, and Mary Owens
Arch Dermatol. 2002;138(9):1165-1171.
ABSTRACT
| FULL TEXT
|
